**PATENT** 

TES STATES PATENT AND TRADEMARK OFFICE

Applicant:

Bernt Swed Asbeck et al

Examiner:

Jeffrey Stucker

Serial No.:

10/049,579

Group Art Unit:

1648

Filed:

February 13, 2002

Docket:

30394-1064

Title:

Bleomycin or Hydroxypyridinon and Virus Inhibiting Combination Pharmaceutical

Composition and Methods (as amended)

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Supplemental Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record.

Because this submission contains only complete copies of articles for which the Examiner cited and provided only an abstract, it is believed that no fee or statement is required with the Supplemental Information Disclosure Statement. However, if an Office Action on the merits has been mailed, the Commissioner is hereby authorized to charge the required fees to Deposit Account No. 13-4213 in order to have this Supplemental Information Disclosure Statement considered.

The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted

Date

December 13, 2004

Slusher, Reg. No. 43,924

Peacock Myers & Adams, P.C. P.O. Box 26927

Albuquerque, New Mexico 87125-6927

505 998 6130

Customer No. 005179

Stephen A Slusher, Reg. No. 43,924

PTC/SB/08A(08-03)
Approved for use through 07/31/2006. OMB 0651-0031
US Patent & Trademark Office: U.S., DEPARTMENT OF COMMERCE
of Information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are Complete if Known Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT 10/049,579 **Application Number** Filing Date February 13, 2002 (Use as many sheets as necessar) **First Named Inventor** Van Asbeck, Bernt DEC 1 6 2004 **Group Art Unit** 1648 TRADEMA **Examiner Name** Jeffrey Stucker Attorney Docket No: 30394-1064 Sheet 1 of 1

US PATENT DOCUMENTS								
Examiner	USP Document	Publication Date	Name of Patentee or	Pages,Columns,Lines,Where Relevant Passages				
Initial *	Number		Applicant of cited Document	or Relevant Figures Appear				

FOREIGN PATENT DOCUMENTS									
Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines, Where Relevant Passages or Relevant Figures Appear	T²				

	OTHE	R DOCUMENTS NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		ANDRUS, L., et al., "Antiretroviral Effects of Deoxyhypusyl Hydroxylase Inhibitors: a Hypusine-Dependent Host Cell Mechanism for Replication of Hu", Biochemical Pharmacology (1998 Jun 1) Vol 55, No. 11, (06/01/1998),1807-18	
		OHTA, K, et al., "Action of a New Mammalian DNA Polymerase Inhibitor Sulfoquinovosyldiacylgylcerol", <u>Biological &amp; Pharmaceutical Bulletin (1999 Feb) Vol. 22</u> , No. 2 pp 111-6 Abstract only,	